Global Blood Therapeutics Inc. (GBT) Plunges 5.42% on March 12

Equities Staff  |

Global Blood Therapeutics Inc. (GBT) had a rough trading day for Monday March 12 as shares tumbled 5.42%, or a loss of $-3.1 per share, to close at $54.05. After opening the day at $57.10, shares of Global Blood Therapeutics Inc. traded as high as $57.30 and as low as $53.90. Volume was 1.82 million shares over 12,097 trades, against an average daily volume of 1.18 million shares and a total float of 47.06 million.

As a result of the decline, Global Blood Therapeutics Inc. now has a market cap of $2.54 billion. In the last year, shares of Global Blood Therapeutics Inc. have traded between a range of $68.05 and $24.03, and its 50-day SMA is currently $56.08 and 200-day SMA is $37.84.

For a complete fundamental analysis of Global Blood Therapeutics Inc., check out’s Stock Valuation Analysis report for GBT.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

Global Blood Therapeutics Inc. is based out of South San Francisco, CA and has some 147 employees. Its CEO is Ted W. Love.

Global Blood Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Global Blood Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: GBT’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change